Corbus Pharmaceuticals Holdings, Inc. (CRBP)Healthcare | Biotechnology | Norwood, United States | NasdaqCM
10.91 USD
-0.22
(-1.977%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 11.10 +0.19 (1.742%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:18 a.m. EDT
The investment case here is fractured by a stark contradiction between the analyst consensus and the hard reality of the business. While analysts project a mean target price of $34.50, implying a massive upside, the company's fundamentals tell a story of severe distress. The stock has lost over 90% of its value over the last nine years, and the most recent annual performance was another catastrophic drop of roughly 84%. The balance sheet is bleeding cash, with negative free cash flow and a return on equity of nearly -96%, while the forward P/E is negative due to expected losses. This is not a value trap; it is a value destruction machine currently propped up by speculative options flow betting on a clinical trial success. The recent news of FDA alignment on a registrational strategy is a necessary condition for survival, but without proven revenue growth or a path to profitability, the long-term outlook remains deeply bearish. For now, the stock is a high-risk speculative vehicle for traders hoping for a binary event, but a terrible long-term investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.110944 |
| AutoARIMA | 0.146036 |
| AutoETS | 0.146037 |
| AutoTheta | 0.246571 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 5.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.148 |
| Excess Kurtosis | -0.62 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.171 |
| Market Cap | 211,013,488 |
| Forward P/E | -1.98 |
| Beta | 2.62 |
| Website | https://www.corbuspharma.com |
As of Aug. 22, 2026, 1:18 a.m. EDT: Speculators are positioning for continued volatility rather than a directional breakout. Call open interest is heavily skewed toward out-of-the-money strikes ($15 and $20), suggesting a speculative bet on a recovery to previous highs, while put open interest concentrates at lower strikes ($2.50 and $7.50), indicating a hedge against further downside. The massive disparity in implied volatility between deep OTM calls and deep ITM/OTM puts highlights a 'long gamma' environment where the market expects large swings but remains agnostic on the final destination.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.12012315 |
| Address1 | 500 River Ridge Drive |
| All Time High | 323.4 |
| All Time Low | 2.11 |
| Ask | 12.42 |
| Ask Size | 1 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 634,270 |
| Average Daily Volume3 Month | 435,558 |
| Average Volume | 435,558 |
| Average Volume10Days | 634,270 |
| Beta | 2.62 |
| Bid | 9.44 |
| Bid Size | 1 |
| Book Value | 5.476 |
| City | Norwood |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.91 |
| Current Ratio | 5.714 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 11.29 |
| Day Low | 10.745 |
| Debt To Equity | 4.171 |
| Display Name | Corbus Pharmaceuticals |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -106,678,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.912 |
| Enterprise Value | 97,336,504 |
| Eps Current Year | -5.434 |
| Eps Forward | -5.51333 |
| Eps Trailing Twelve Months | -5.98 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.4432 |
| Fifty Day Average Change | 1.4667997 |
| Fifty Day Average Change Percent | 0.15532868 |
| Fifty Two Week Change Percent | 12.012315 |
| Fifty Two Week High | 20.56 |
| Fifty Two Week High Change | -9.65 |
| Fifty Two Week High Change Percent | -0.46935797 |
| Fifty Two Week Low | 7.12 |
| Fifty Two Week Low Change | 3.79 |
| Fifty Two Week Low Change Percent | 0.5323034 |
| Fifty Two Week Range | 7.12 - 20.56 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,414,416,600,000 |
| Float Shares | 15,159,899 |
| Forward Eps | -5.51333 |
| Forward P E | -1.9788404 |
| Free Cashflow | -49,618,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 36 |
| Fullday Change | -0.22 |
| Fullday Change Percent | -1.97664 |
| Fullday Price | 11.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -90,260,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01197 |
| Held Percent Institutions | 0.73452 |
| Implied Shares Outstanding | 19,341,293 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,676,332,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts. |
| Long Name | Corbus Pharmaceuticals Holdings, Inc. |
| Market | us_market |
| Market Cap | 211,013,488 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_254045988 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -101,903,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 215,268,591 |
| Number Of Analyst Opinions | 10 |
| Open | 11.13 |
| Operating Cashflow | -86,668,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 617 963 0100 |
| Post Market Change | 0.19000053 |
| Post Market Change Percent | 1.7415265 |
| Post Market Price | 11.1 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 11.13 |
| Price Eps Current Year | -2.007729 |
| Price Hint | 2 |
| Price To Book | 1.9923302 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.56 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | -0.22 |
| Regular Market Change Percent | -1.97664 |
| Regular Market Day High | 11.29 |
| Regular Market Day Low | 10.745 |
| Regular Market Day Range | 10.745 - 11.29 |
| Regular Market Open | 11.13 |
| Regular Market Previous Close | 11.13 |
| Regular Market Price | 10.91 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 583,248 |
| Return On Assets | -0.52999 |
| Return On Equity | -0.9558 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 19,341,293 |
| Shares Percent Shares Out | 0.111 |
| Shares Short | 2,147,752 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,096,262 |
| Short Name | Corbus Pharmaceuticals Holdings |
| Short Percent Of Float | 0.1271 |
| Short Ratio | 7.19 |
| Source Interval | 15 |
| State | MA |
| Symbol | CRBP |
| Target High Price | 48.0 |
| Target Low Price | 17.25 |
| Target Mean Price | 34.025 |
| Target Median Price | 34.0 |
| Total Cash | 117,941,000 |
| Total Cash Per Share | 6.098 |
| Total Debt | 4,264,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.98 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.279075 |
| Two Hundred Day Average Change | 1.6309252 |
| Two Hundred Day Average Change Percent | 0.17576377 |
| Type Disp | Equity |
| Volume | 583,248 |
| Website | https://www.corbuspharma.com |
| Zip | 2,062 |